Decitabine

Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and a DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell apoptosis. Decitabine has potent anticancer activity[1][2].

Product Specifications

CAS Number

[2353-33-5]

Product Name Alternative

5-Aza-2'-deoxycytidine; 5-AZA-CdR; NSC 127716

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335, H341, H360

Target

Apoptosis; DNA Methyltransferase; Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Decitabine.html

Concentration

10mM

Purity

99.97

Solubility

DMSO : ≥ 50 mg/mL|H2O : 20 mg/mL (ultrasonic)

Smiles

O[C@H]1C[C@H](N2C(N=C(N)N=C2)=O)O[C@@H]1CO

Molecular Formula

C8H12N4O4

Molecular Weight

228.21

Precautions

H302, H315, H319, H335, H341, H360

References & Citations

[1]Nakamura M, et al. Decitabine inhibits tumor cell proliferation and up-regulates E-cadherin expression in Epstein-Barr virus-associated gastric cancer. J Med Virol. 2016 Jul 19.|[2]Hagemann S, et al. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One. 2011 Mar 7;6 (3) :e17388.|[3]Requena CE, et al. The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine. Biochem J. 2016 Jun 20.|[4]Terse P, et al. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Int J Toxicol. 2014 Mar-Apr;33 (2) :75-85.|[5]Yu J, et al. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest. 2018 Jun 1;128 (6) :2376-2388.|[6]Wang LX, et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumorspecific cytotoxic T lymphocyte responses. PLoS One. 2013 May 9;8 (5) :e62924.|[7]Parker WB. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev. 2009 Jul;109 (7) :2880-93.